Malcavernin Inhibitors
Chemical inhibitors of Malcavernin can achieve their inhibitory effects through multiple pathways, primarily by targeting the RhoA/ROCK pathway, which is integral to Malcavernin's role in maintaining vascular integrity and stability. Fasudil and its active metabolite Hydroxyfasudil, along with Y-27632, directly inhibit ROCK, which is a downstream effector in the RhoA pathway. The inhibition of ROCK leads to decreased stress fiber formation and cellular contractility, both of which are important for the stabilization of endothelial junctions where Malcavernin is known to be active. Similarly, Amiloride indirectly influences the RhoA/ROCK pathway by modulating intracellular sodium levels, which affect cellular contractility and adherence junction stability, ultimately impacting Malcavernin function.
In addition to these direct ROCK inhibitors, CCG-1423 targets the RhoA/serum response factor (SRF) signaling pathway. This pathway is connected to Malcavernin's role in regulating cell shape and motility, and its inhibition would lead to a reduction in Malcavernin's activity in these processes. A group of chemicals, namely Simvastatin, Lovastatin, Atorvastatin, and Pitavastatin, inhibit the mevalonate pathway. This is critical for the prenylation and subsequent activation of small GTPases like RhoA. By reducing the activation of RhoA, these statins can indirectly inhibit Malcavernin's role in cytoskeletal organization and endothelial barrier function. Manumycin A and GGTI-298 further inhibit the prenylation and activation of RhoA by targeting farnesyltransferase and geranylgeranyltransferase I, respectively, leading to inhibition of Malcavernin-associated cellular functions.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Fasudil, Monohydrochloride Salt | 105628-07-7 | sc-203418 sc-203418A sc-203418B sc-203418C sc-203418D sc-203418E sc-203418F | 10 mg 50 mg 250 mg 1 g 2 g 5 g 10 g | $18.00 $33.00 $87.00 $168.00 $253.00 $496.00 $910.00 | 5 | |
Fasudil is a Rho kinase inhibitor which blocks the RhoA/ROCK pathway. Malcavernin is known to interact with the RhoA pathway, and inhibition of this pathway by Fasudil can lead to decreased stress fiber formation and reduced stabilization of endothelial junctions, thereby inhibiting the functional role of Malcavernin in maintaining vascular integrity. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is another inhibitor of the Rho-associated protein kinase (ROCK). By inhibiting ROCK, this chemical reduces actomyosin contractility, which can lead to the inhibition of Malcavernin's function related to cytoskeletal organization and cellular contraction, processes Malcavernin is involved in through its interaction with the RhoA pathway. | ||||||
Amiloride | 2609-46-3 | sc-337527 | 1 g | $296.00 | 7 | |
Amiloride indirectly inhibits the RhoA/ROCK pathway by modulating intracellular sodium levels, which can affect cellular contractility and adherence junction stability. This can inhibit Malcavernin's role in cell-cell junction regulation and cytoskeletal organization. | ||||||
CCG-1423 | 285986-88-1 | sc-205241 sc-205241A | 1 mg 5 mg | $30.00 $90.00 | 8 | |
CCG-1423 inhibits the RhoA/serum response factor (SRF) signaling pathway. Since Malcavernin is part of the CCM signaling complex that interacts with RhoA, inhibition of this pathway can lead to a reduction in Malcavernin's activity related to cellular shape and motility regulation. | ||||||
Simvastatin | 79902-63-9 | sc-200829 sc-200829A sc-200829B sc-200829C | 50 mg 250 mg 1 g 5 g | $31.00 $89.00 $135.00 $443.00 | 13 | |
Simvastatin inhibits the mevalonate pathway, which is critical for the prenylation and activation of small GTPases like RhoA. By inhibiting RhoA activation, Simvastatin can indirectly inhibit Malcavernin's function in the stabilization of endothelial junctions. | ||||||
Lovastatin | 75330-75-5 | sc-200850 sc-200850A sc-200850B | 5 mg 25 mg 100 mg | $29.00 $90.00 $339.00 | 12 | |
Lovastatin, similar to Simvastatin, inhibits the mevalonate pathway, thereby reducing the prenylation and activation of RhoA. This leads to inhibition of Malcavernin-mediated activities in cytoskeletal dynamics and endothelial barrier function. | ||||||
Atorvastatin | 134523-00-5 | sc-337542A sc-337542 | 50 mg 100 mg | $257.00 $505.00 | 9 | |
Atorvastatin also inhibits the mevalonate pathway and has a similar mode of action as Simvastatin and Lovastatin. It indirectly inhibits Malcavernin by reducing RhoA activation, which Malcavernin interacts with for cellular junction stability and vascular integrity. | ||||||
Manumycin A | 52665-74-4 | sc-200857 sc-200857A | 1 mg 5 mg | $219.00 $634.00 | 5 | |
Manumycin A is a farnesyltransferase inhibitor that can prevent the activation of RhoA by inhibiting its farnesylation. By doing so, this chemical can inhibit the interaction of Malcavernin with the RhoA pathway, affecting cellular shape and vascular stability. | ||||||
GGTI 298 | 1217457-86-7 | sc-361184 sc-361184A | 1 mg 5 mg | $193.00 $838.00 | 2 | |
GGTI-298 inhibits geranylgeranyltransferase I, necessary for the geranylgeranylation of RhoA, which is essential for its activation. Inhibition of RhoA activation can disrupt Malcavernin-mediated regulation of endothelial barrier function. | ||||||